Stockreport

Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts [Yahoo! Finance]

Nurix Therapeutics, Inc. - Common stock  (NRIX) 
PDF TheFly reported on January 29 that Stifel raised the price target on NRIX to $35 from $33 and maintained a Buy rating. The firm noted that 2026 will be a key year for b [Read more]